EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice

Kim Thi Hoang Do, Stefanie Willenzon, Jasmin Ristenpart, Anika Janssen, Asisa Volz, Gerd Sutter, Reinhold Förster, Berislav Bošnjak

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2023.1259822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Kim Thi Hoang Do und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Immunology, Hannover Medical School, Hannover, Germany. Hauptthemen laut MEDLINE: COVID-19, Vaccines. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft, Niedersächsische Ministerium für Wissenschaft und Kultur, Bundesministerium für Bildung und Forschung.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aims Modified Vaccinia virus Ankara (MVA) represents a promising vaccine vector for respiratory administration to induce protective lung immunity including tertiary lymphoid structure, the bronchus-associated lymphoid tissue (BALT). However, MVA expressing the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike protein (MVA-SARS-2-S) required prime-boost administration to induce high titers of anti-Spike antibodies in serum and bronchoalveolar lavage (BAL). As the addition of adjuvants enables efficient tailoring of the immune responses even to live vaccines, we tested whether Toll-like receptor (TLR)-agonists affect immune responses induced by a single dose of intranasally applied MVA-SARS-2-S.

Methods

We intranasally immunized C57BL/6 mice with MVA-SARS-2-S vaccine in the presence of either TLR3 agonist polyinosinic polycytidylic acid [poly(I:C)], TLR4 agonist bacterial lipopolysaccharide (LPS) from Escherichia coli , or TLR9 agonist CpG oligodeoxynucleotide (CpG ODN) 1826. At different time-points after immunization, we analyzed induced immune responses using flow cytometry, immunofluorescent microscopy, and ELISA.

Results

TLR agonists had profound effects on MVA-SARS-2-S-induced immune responses. At day 1 post intranasal application, the TLR4 agonist significantly affected MVA-induced activation of dendritic cells (DCs) within the draining bronchial lymph nodes, increasing the ratio of CD11b + CD86 + to CD103 + CD86 + DCs. Nevertheless, the number of Spike-specific CD8 + T cells within the lungs at day 12 after vaccination was increased in mice that received MVA-SARS-2-S co-administered with TLR3 but not TLR4 agonists. TLR9 agonist did neither significantly affect MVA-induced DC activation nor the induction of Spike-specific CD8 + T cells but reduced both number and size of bronchus-associated lymphoid tissue. Surprisingly, the addition of all TLR agonists failed to boost the levels of Spike-specific antibodies in serum and bronchoalveolar lavage.

Conclusions

Our study indicates a potential role of TLR-agonists as a tool to modulate immune responses to live vector vaccines. Particularly TLR3 agonists hold a promise to potentiate MVA-induced cellular immune responses. On the other hand, additional research is necessary to identify optimal combinations of agonists that could enhance MVA-induced humoral responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19VaccinesAnimalsMiceSARS-CoV-2Administration, IntranasalCD8-Positive T-LymphocytesToll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 9Mice, Inbred C57BLVaccinia virusAdjuvants, ImmunologicAntibodies, Viral

Stichwörter der Autor:innen

Toll-like receptor (TLR) agonistmodified vaccinia virus Ankara (MVA)respiratory tractsevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)vaccination

Substanzen

Toll-Like Receptor 3Toll-Like Receptor 4Toll-Like Receptor 9Adjuvants, ImmunologicVaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Institute of Immunology, Hannover Medical School, Hannover, Germany.
  • Institute for Virology, University of Veterinary Medicine Hannover, Hannover, Germany.
  • German Centre for Infection Research (DZIF), Munich, Germany.
  • Division of Virology, Department of Veterinary Sciences, Ludwig Maximiliam University (LMU) Munich, Munich, Germany.
  • Cluster of Excellence RESIST (EXC 2155), Hannover Medical School, Hannover, Germany.
  • German Centre for Infection Research (DZIF), Hannover, Germany.

Förderung

  • Deutsche Forschungsgemeinschaft
  • Niedersächsische Ministerium für Wissenschaft und Kultur
  • Bundesministerium für Bildung und Forschung
  • Deutsches Zentrum für Lungenforschung

Zitieren

APA

Do, K. T. H., Willenzon, S., Ristenpart, J., Janssen, A., Volz, A., Sutter, G., Förster, R., & Bošnjak, B. (2023). The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2023.1259822

Vancouver

Do KTH, Willenzon S, Ristenpart J, Janssen A, Volz A, Sutter G, et al. The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2023.1259822

BibTeX
@article{Do2023,
  author = {Do, Kim Thi Hoang and Willenzon, Stefanie and Ristenpart, Jasmin and Janssen, Anika and Volz, Asisa and Sutter, Gerd and Förster, Reinhold and Bošnjak, Berislav},
  title = {The effect of Toll-like receptor agonists on the immunogenicity of MVA-SARS-2-S vaccine after intranasal administration in mice},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2023.1259822}
}
Kostenlos starten →